Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

20.48
+0.51002.55%
Post-market: 20.650.1700+0.83%19:55 EDT
Volume:2.92M
Turnover:59.42M
Market Cap:2.15B
PE:-2.87
High:20.62
Open:19.93
Low:19.81
Close:19.97
52wk High:72.05
52wk Low:10.42
Shares:104.79M
Float Shares:95.17M
Volume Ratio:0.43
T/O Rate:3.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.1300
EPS(LYR):-7.1300
ROE:-53.47%
ROA:-11.24%
PB:1.88
PE(LYR):-2.87

Loading ...

Shares of This Gene Therapy Maker Are Up 29%. The Safety Debate Is Far From Over. -- Barrons.com

Dow Jones
·
Mar 26

Sarepta initial siRNA data ‘thin and somewhat mixed,’ says Leerink

TIPRANKS
·
Mar 25

Sarepta early DM1 data ‘appear promising,’ says Oppenheimer

TIPRANKS
·
Mar 25

Sarepta Therapeutics' Early Trial Results of siRNA Treatments Show High Muscle Concentrations in Neuromuscular Diseases

MT Newswires Live
·
Mar 25

Shares of Sarepta Therapeutics up 3.2% Premarket After Muscle Disease Drugs Show Promise in Early-to-Mid Stage Trials

THOMSON REUTERS
·
Mar 25

BRIEF-Sarepta Announces First Clinical Data From Sirna Pipeline Targeting Fshd1 And Dm1

Reuters
·
Mar 25

BUZZ-Sarepta rises after muscle disease drugs show promise in early-to-mid stage trials

Reuters
·
Mar 25

Sarepta Therapeutics Inc - Proof-of-Concept Data Show Single Dose of Srp-1001 and Srp-1003 Reduces Target Protein or Mrna

THOMSON REUTERS
·
Mar 25

Sarepta Therapeutics Inc - Majority of Adverse Events in Studies Were Mild to Moderate and Not Dose Dependent

THOMSON REUTERS
·
Mar 25

Sarepta Therapeutics Inc - Sirna Achieves High Muscle Concentrations Without Dose Limiting Toxicity for Fshd1 and Dm1

THOMSON REUTERS
·
Mar 25

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Rezolute (RZLT) and Demant (OtherWILLF)

TIPRANKS
·
Mar 25

Sarepta to present Phase 1/2 data for SRP-1001 in FSHD1 and SRP-1003 in DM1

Reuters
·
Mar 25

Sarepta pre-May sNDA plan points to constructive FDA dialogue, says Oppenheimer

TIPRANKS
·
Mar 19

Sarepta provides regulatory update on Amondys 45, Vyondys 53

TIPRANKS
·
Mar 19

Sarepta plans FDA sNDA filings by end of April 2026 to seek traditional approval for AMONDYS 45 and VYONDYS 53

Reuters
·
Mar 19

Sarepta Therapeutics Inc - FDA Confirms Sarepta Can Submit Essence Study and Real-World Evidence for Sndas

THOMSON REUTERS
·
Mar 19

Sarepta Provides Regulatory Update on Amondys 45® and Vyondys 53®

THOMSON REUTERS
·
Mar 19

Sarepta Therapeutics Inc - to Submit Sndas to FDA by End of April 2026 for Traditional Approval

THOMSON REUTERS
·
Mar 19

Sarepta Therapeutics Inc: Requested a Meeting With FDA to Discuss Submitting Supplemental New Drug Applications

THOMSON REUTERS
·
Mar 19

Cantor Fitzgerald Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)

TIPRANKS
·
Mar 17